May 2015-April 2016

Press Release

  • 28 April 2016
    Partnership Agreement concluded with Kaplan regarding sales and marketing of absorbable local hemostat "PuraStat®"in Chile
  • 05 April 2016
    [Delayed] Patent Granted for "Cardiac Tissue Regeneration" with Self-Assembling Peptide Technology in Japan
  • 22 February 2016
    Absorbable Hemostat PuraStat® Product Registration Obtained in Mexico
  • 18 February 2016
    Partnership Agreement concluded with Genelife S.A regarding sales and marketing of absorbable local hemostat "PuraStat®" in Mexico
  • 15 February 2016
    Announcement of Change of Representative Directors
  • 10 February 2016
    Revision of Forecast of Financial Results for FY2015 and Extraordinary loss
  • 25 January 2016
    Absorbable Hemostat PuraStat® Product Registration Obtained in Thailand
  • 22 January 2016
    Absorbable Hemostat PuraStat® Product Registration Obtained in Australia
  • 05 January 2016
    Patent granted on "3-D Cell Culture Scaffold" in Canada with self-assembling peptide technology exclusively licensed by MIT
  • 28 December 2015
    Partnership Agreement concluded with Transmedic Pte Ltd regarding sales and marketing of 「PuraStat®」in Singapore, Malaysia and Brunei
  • 04 November 2015
    Absorbable Hemostat "TDM-621" Product Registration Obtained in Brazil
  • 05 October 2015
    Partnership Agreement concluded with Maquet Australia Pty Ltd regarding sales and marketing of absorbable local hemostat 「PuraStat®」in Australia
  • 15 September 2015
    Patent Granted for "Transfection Agent (Agent for Transfer of Nucleic Acids into Cells)" Using the 3D-Matrix Peptide Technology
  • 23 July 2015
    Absorbable Hemostat "TDM-621" Product Registration Obtained in Colombia
  • 10 July 2015
    Partnership Agreement concluded with Daewoong Pharmaceutical Co., Ltd. regarding sales and marketing of absorbable local hemostat 「PuraStat®」in ASEAN
  • 7 July 2015
    Start of an Investigator-Initiated Clinical Trial for Treatment-Resistant Breast Cancer Patients with Novel siRNA Nucleic Acid Formulation “TDM-812” at the National Cancer Center
  • 27 May 2015
    Subsidiary Foundation in the Netherlands

Consolidated Financial Report

  • 15 Mar 2016
    CONSOLIDATED FINANCIAL REPORT For the Third Quarter of Fiscal Year Ending April 30, 2016 (Under Japan GAAP)
  • 16 December 2015
    CONSOLIDATED FINANCIAL REPORT For the Second Quarter of Fiscal Year Ending April 30, 2016
  • 7 September 2015
    For the First Quarter of Fiscal Year Ending April 30, 2016 (Under Japan GAAP)
  • 12 June 2015
    Consolidated Financial Report For the Fiscal Year Ended April 30, 2015 (Under Japan GAAP)

Mid-Term Business Plan

  • 12 June 2015
    FY2015-FY2017 Mid-Term Business Plan

Most Recent Financial Statements

  •  

Other

  • 26 January 2016
    Business Analysis Report by Shared Research Inc.
  • 2 October 2015
    Business Analysis Report by Shared Research Inc.
  • 7 September 2015
    Business Analysis Report by Shared Research Inc.
  • 12 June 2015
    Business Analysis Report by Shared Research Inc.
May 2014-April 2015

Press Release

  • 16 April 2015
    Absorbable Hemostat「PuraStat®」Product Registration Obtained in Indonesia
  • 13 March 2015
    Withdrawal of Application for the Approval of the Hemostat (TDM-621)
  • 13 March 2015
    Revision of Forecast of Financial Results for FY2014 and Reduction of Board Members' Compensation
  • 13 March 2015
    [Delayed]Revision of Mid-term Business Plan (FY2014-FY2016)
  • 9 March 2015
    Absorbable Hemostat "PuraStat®" Product Registration Application Submitted in Colombia
  • 18 February 2015
    [Delayed] Approval of a premarket notification 510(k) of wound healing material (TDM-511) in the US
  • 18 February 2015
    [Delayed] Suspension of Patient Enrolment in the Clinical Trial of "Mucous Membrane Protuberance Material (TDM-641)"
  • 29 January 2015
    Absorbable Hemostat "PuraStat®" Product Registration Application Submitted in Korea
  • 27 January 2015
    3-D Matrix Ltd.´s Subsidiary Signs New Exclusive Patent License Agreements with Massachusetts Institutes of Technology (MIT)
  • 22 December 2014
    Absorbable Hemostat "PuraStat®" Commencement of clinical use in the field of endoscopy
  • 22 December 2014
    Termination of Semi-Exclusive Partnership Agreement Regarding Marketing Alliance of Absorbable Hemostat "TDM-621" Between Fuso Pharmaceutical
  • 3 November 2014
    Patent Granted on "Modified Peptides" with Self-Assembling Peptide Technology that 3-D Matrix has exclusive license
  • 1 December 2014
    [Delayed] Announcement of launch of the comprehensive research and development project for creating the culture product kit using "ReproHepato™: human iPS cell derived hepatocyte," a cell product of ReproCELL Incorporated, and "PuraMatrix®," a product of 3-D Matrix, Ltd.
  • 6 November 2014
    Absorbable Hemostat "PuraStat®" Implementation of clinical use in Hong Kong
  • 4 November 2014
    Absorbable Hemostat "PuraStat®" Commencement of clinical use in Chile
  • 10 Ocember 2014
    Announcement of submission of a premarket notification 510 (k) for approval of wound healing material (TDM-511) in the U.S.
  • 10 September 2014
    Patent Granted for "Transfection Agent (Agent for Transfer of Genes into Cells)" Using the 3-D Matrix Peptide Technology
  • 9 September 2014
    Clinical Trial Application for The Endoscopic Mucosal Resection Aid "Submucosal Injection Material for Endoscopy (TDM-641)"
  • 3 September 2014
    Absorbable Hemostat "PuraStat®" Product Registration Obtained in Singapore
  • 1 September 2014
    Subsidiary Foundation in China
  • 28 August 2014
    Absorbable Hemostat "PuraStat®" Commencement of clinical use in Germany
  • 12 August 2014
    [Delayed]Amicable Settlement of Litigation and Recognition of Extraordinary Loss
  • 18 July 2014
    Absorbable Hemostat “TDM-621” Product Registration Application Submitted in Indonesia
  • 14 July 2014
    Absorbable Hemostat "PuraStat®" Commencement of clinical use in the European Union
  • 23 June 2014
    [Delayed] Patent Granted for "Cardiac Tissue Regeneration" with Self-Assembling Peptide Technology
  • 17 June 2014
    Subsidiary Foundation in Brazil
  • 05 June 2014
    Patent Granted in Europe on Use of Lipid-Like Self-Assembling Peptide Surfactant Technology as "Transfection Agent"
  • 04 June 2014
    Absorbable Hemostat "TDM-621" Product Registration Application Submitted in Singapore
  • 30 May 2014
    Patent Granted on "Pancreatic Regeneration" with Self-assemblinging Peptide Technology
  • 12 May 2014
    License Agreement on Self-Assembled Ultrashort Peptide Technology

Consolidated Financial Report

  • 13 Mar 2015
    Consolidated Financial Report For the Third Quarter of Fiscal Year Ending April 30, 2015 (Under Japan GAAP)
  • 11 Dec 2014
    Consolidated Financial Report For the Second Quarter of Fiscal Year Ending April 30, 2015 (Under Japan GAAP)
  • 12 Sep 2014
    For the First Quarter of Fiscal Year Ending April 30, 2015 (Under Japan GAAP)
  • 19 June 2014
    [Delayed] Consolidated Financial Report For the Fiscal Year Ended April 30, 2014 (Under Japan GAAP)

Mid-Term Business Plan

  • 19 June 2014
    [Delayed] FY2014-FY2016 Mid-Term Business Plan

Most Recent Financial Statements

  •  

Other

  • 31 March 2015
    Business Analysis Report by Shared Research Inc.
  • 07 January 2015
    Business Analysis Report by Shared Research Inc.
  • 29 September 2014
    Business Analysis Report by Shared Research Inc.
May 2013-April 2014

Press Release

  • 02 Apl 2014
    [Delayed] Patent Granted in Japan on “Wound Healing and Skin Regeneration Material”with Self-assembling Peptide Technology
  • 14 Mar 2014
    Revision of Forecast of Financial Results for FY2013
  • 14 Mar 2014
    Revision of Mid-term Business Plan (FY2013-FY2015)
  • 10 Mar 2014
    [Delayed] Notice Regarding Exercise Price of Share Warrants
  • 24 Feb 2014
    [Delayed] Issuance of Share Warrants
  • 13 Feb 2014
    Patent Granted in US on “Pancreatic Regeneration” with Self-assembling Peptide Technology
  • 31 Jan 2014
    MIT and 3-D Matrix, Inc. Files Patent Infringement Complaint Against Menicon Co. Ltd. and B-Bridge International Inc.
  • 15 Jan 2014
    Surgical Hemostat(TDM-621):CE Marking Certificate Issued
  • 08 Nov 2013
    [Delayed] 3-D Matrix Nominated in "COI STREAM Program"
  • 31 May 2013
    [Delayed] Partnership Agreement concluded with PT. Teguhsindo Lestaritama regarding sales and marketing of surgical hemostat (TDM-621) in Indonesia
  • 28 May 2013
    [Delayed] Patent Granted on “Hepatic and Pancreatic Regeneration” with Self-assembling Peptide Technology
  • 21 May 2013
    [Delayed] Surgical Hemostat(TDM-621)Application for CE Marking
  • 16 May 2013
    [Delayed] Stock Split and Partial Amendment to the Articles of Incorporation

Consolidated Financial Report

  • 14 Mar 2014
    For the Third Quarter of Fiscal Year Ending April 30, 2014 (Under Japan GAAP)
  • 06 Dec 2013
    For the Second Quarter of Fiscal Year Ending April 30, 2014(Under Japan GAAP)

Mid-Term Business Plan

  • 14 Mar 2014
    FY2013-FY2015 Mid-Term Business Plan
  • 13 June 2013
    FY2013-FY2015 Mid-Term Business Plan

Most Recent Financial Statements

  •  

Other

  • 25 March 2014
    Business Analysis Report by Shared Research Inc.
  • 24 December 2013
    Business Analysis Report by Shared Research Inc.
  • 2 July 2013
    Business Analysis Report by Shared Research Inc.
May 2012-April 2013

Press Release

  • 23 April 2013
    Revision of Forecast of Financial Results for FY2012
  • 23 April 2013
    Revision of Mid-term Business Plan
  • 21 March 2013
    ISO13485 Approval International Standard of Quality Management System
  • 04 February 2013
    Surgical Hemostat (TDM-621):IDE Submission to FDA
  • 01 February 2013
    Revision of Forecast of Financial Results for FY2012
  • 01 February 2013
    Revision of Mid-term Business Plan

  • 20 November 2012
    Patent Granted on "Cardiac Tissue Protection and Regeneration" with Self-assembling Peptide Technology
  • 15 November 2012
    (Announcement) Subsidiary foundation Completed
  • 16 October 2012
    (Announcement) 3DM Ranked 11th in “Technology Fast50 Japan”
  • 15 October 2012
    (Announcement) Subsidiary foundation
  • 25 September 2012
    Semi-exclusive distribution agreement concluded with Fuso Pharmaceutical Industries, Ltd. and Kaken Pharmaceutical Co., Ltd. regarding absorbable local hemostat (TDM-621)
  • 18 September 2012
    (Announcement) 3DM Selected as a Component of J-Stock Index
  • 06 September 2012
    Patent Granted on "Modified Peptide" with Self-assembling Peptide Technology
  • 05 September 2012
    Patent Granted on "Chondrocyte Cultivation" with Self-assembling Peptide Technology
  • 03 September 2012
    (Announcement) Stock Split
  • 16 August 2012
    Notice Regarding Exercise Price of Share Warrants
  • 31 July 2012
    3-D Matrix nominated as a joint research partner in Grants-in Aid for Scientific Research Project on non-clinical study for innovative cancer treatment
  • 17 July 2012
    (Announcement) Stock Split and Partial Amendment to the Articles of Incorporation
  • 26 June 2012
    Notice Regarding Change in Director and New Board Members
  • 18 June 2012
    Progress report of clinical trial on “Bone Void Filler TDM-711”

Consolidated Financial Report

Mid-Term Business Plan

  • 23 April 2013
    FY2012-FY2014 Mid-Term Business Plan(Revised)
  • 01 February 2013
    FY2012-FY2014 Mid-Term Business Plan
  • 14 June 2012
    FY2012-FY2014 Mid-Term Business Plan

Most Recent Financial Statements

  •  

Other

  • 29 March 2013
    Business Analysis Report by Shared Research Inc.
  • 24 September 2012
    Business Analysis Report by Shared Research Inc.
May 2011-April 2012

Press Release

  • 17 April 2012
    (Announcement) Subsidiary foundation Completed
  • 09 April 2012
    Memorandum of Understanding concluded with Fuso Pharmaceutical Industries, Ltd. and Kaken Pharmaceutical Co., Ltd. regarding sales of absorbable local hemostat (TDM-621)
  • 02 March 2012
    Clinical study with 3DM’s technology started at School of Medicine, Keio University
  • 22 February 2012
    Clinical trial started in U.S. about dental implant product “Alveolar Rebuilding TDM-711”
  • 20 February 2012
    Exclusive distribution license agreement concluded with Fuso Pharmaceutical Industries, Ltd. regarding mucous membrane raising device (TDM-641).
  • 17 January 2012
    (Announcement) Subsidiary foundation

  • 04 November 2011
    3-D Matrix nominated as a joint research partner in Grants-in Aid for Scientific Research Project on triple negative breast cancer treatment.

Consolidated Financial Report

Mid-Term Business Plan

Most Recent Financial Statements

  •  

Other

Change character size